Priscilla Kalliope Brastianos, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 26 | 2018 | 9071 | 2.030 |
Why?
|
| Meningeal Neoplasms | 10 | 2018 | 1252 | 1.360 |
Why?
|
| Meningioma | 9 | 2018 | 1221 | 1.240 |
Why?
|
| Craniopharyngioma | 3 | 2015 | 276 | 1.180 |
Why?
|
| Molecular Targeted Therapy | 8 | 2018 | 2822 | 1.020 |
Why?
|
| Meningeal Carcinomatosis | 2 | 2017 | 65 | 0.910 |
Why?
|
| Pituitary Neoplasms | 4 | 2016 | 1321 | 0.860 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2015 | 2054 | 0.720 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2018 | 916 | 0.620 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2010 | 754 | 0.600 |
Why?
|
| Seminoma | 1 | 2018 | 134 | 0.560 |
Why?
|
| Dystrophin | 1 | 2018 | 283 | 0.550 |
Why?
|
| Meningitis | 1 | 2018 | 216 | 0.540 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2011 | 2056 | 0.520 |
Why?
|
| Gene Fusion | 1 | 2018 | 357 | 0.480 |
Why?
|
| Antineoplastic Agents | 7 | 2017 | 13648 | 0.460 |
Why?
|
| Radiotherapy | 2 | 2017 | 1494 | 0.420 |
Why?
|
| Poetry as Topic | 1 | 2012 | 17 | 0.400 |
Why?
|
| Genomics | 3 | 2016 | 5929 | 0.370 |
Why?
|
| Gene Deletion | 1 | 2018 | 2666 | 0.360 |
Why?
|
| Point Mutation | 1 | 2015 | 1590 | 0.350 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 788 | 0.340 |
Why?
|
| Melanoma | 4 | 2016 | 5719 | 0.340 |
Why?
|
| Glioma | 6 | 2018 | 3493 | 0.330 |
Why?
|
| Carbazoles | 3 | 2016 | 229 | 0.330 |
Why?
|
| Neovascularization, Pathologic | 2 | 2010 | 2631 | 0.330 |
Why?
|
| Neurosurgical Procedures | 2 | 2017 | 2074 | 0.330 |
Why?
|
| Sacrum | 2 | 2009 | 270 | 0.320 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2009 | 70 | 0.300 |
Why?
|
| Skin Neoplasms | 3 | 2016 | 5849 | 0.290 |
Why?
|
| Primary Myelofibrosis | 1 | 2009 | 210 | 0.290 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2018 | 954 | 0.260 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 1242 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 2453 | 0.240 |
Why?
|
| Osteochondroma | 1 | 2005 | 44 | 0.240 |
Why?
|
| Mutation | 12 | 2018 | 30198 | 0.240 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2012 | 1376 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2880 | 0.230 |
Why?
|
| Injections, Spinal | 2 | 2017 | 310 | 0.220 |
Why?
|
| Valine | 2 | 2015 | 410 | 0.220 |
Why?
|
| Immunotherapy | 2 | 2017 | 4752 | 0.220 |
Why?
|
| Piperidines | 3 | 2016 | 1664 | 0.210 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2006 | 272 | 0.200 |
Why?
|
| Telomerase | 2 | 2018 | 749 | 0.190 |
Why?
|
| Spinal Neoplasms | 2 | 2005 | 708 | 0.190 |
Why?
|
| Humans | 51 | 2018 | 765968 | 0.190 |
Why?
|
| Lung Neoplasms | 6 | 2016 | 13451 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2016 | 9373 | 0.180 |
Why?
|
| Craniotomy | 2 | 2015 | 730 | 0.180 |
Why?
|
| Thoracic Vertebrae | 1 | 2005 | 614 | 0.180 |
Why?
|
| Glutamic Acid | 2 | 2015 | 1180 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2018 | 5696 | 0.170 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2006 | 838 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2009 | 2921 | 0.160 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 9525 | 0.160 |
Why?
|
| Sex Chromatin | 1 | 2018 | 19 | 0.160 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2014 | 258 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 4274 | 0.150 |
Why?
|
| Cyanides | 1 | 2018 | 82 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 1624 | 0.140 |
Why?
|
| Guanidines | 1 | 2018 | 194 | 0.140 |
Why?
|
| Prognosis | 7 | 2018 | 29922 | 0.140 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 684 | 0.130 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2015 | 23 | 0.130 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 385 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 6942 | 0.120 |
Why?
|
| Neurofibromin 2 | 2 | 2014 | 268 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 8529 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 209 | 0.120 |
Why?
|
| Neoplasms | 2 | 2015 | 22340 | 0.120 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 539 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11868 | 0.120 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 437 | 0.120 |
Why?
|
| Hemangioblastoma | 1 | 2014 | 63 | 0.110 |
Why?
|
| Tumor Microenvironment | 3 | 2017 | 3946 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2017 | 2796 | 0.110 |
Why?
|
| Oximes | 1 | 2015 | 305 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2015 | 3655 | 0.110 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 456 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 21056 | 0.110 |
Why?
|
| Cell Line, Tumor | 6 | 2018 | 17075 | 0.110 |
Why?
|
| Cathepsins | 1 | 2014 | 242 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 386 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 303 | 0.100 |
Why?
|
| Pyrimidinones | 1 | 2015 | 384 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2015 | 639 | 0.100 |
Why?
|
| Genotype | 2 | 2018 | 13024 | 0.100 |
Why?
|
| Turner Syndrome | 1 | 2014 | 129 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2016 | 5389 | 0.100 |
Why?
|
| Blood-Brain Barrier | 2 | 2016 | 1037 | 0.100 |
Why?
|
| Gadolinium | 1 | 2017 | 965 | 0.100 |
Why?
|
| Symbolism | 1 | 2012 | 32 | 0.100 |
Why?
|
| Base Sequence | 2 | 2014 | 12403 | 0.100 |
Why?
|
| Simplexvirus | 1 | 2016 | 807 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 735 | 0.100 |
Why?
|
| Cisterna Magna | 1 | 2011 | 39 | 0.090 |
Why?
|
| Disease Progression | 3 | 2018 | 13632 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2018 | 36532 | 0.090 |
Why?
|
| Injections, Intraventricular | 1 | 2011 | 227 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2018 | 10070 | 0.090 |
Why?
|
| Survival | 1 | 2011 | 160 | 0.090 |
Why?
|
| Dancing | 1 | 2012 | 105 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 618 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1009 | 0.090 |
Why?
|
| DNA Modification Methylases | 1 | 2011 | 207 | 0.090 |
Why?
|
| Oncolytic Virotherapy | 1 | 2016 | 520 | 0.090 |
Why?
|
| Pyridones | 1 | 2015 | 816 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 571 | 0.080 |
Why?
|
| Imidazoles | 1 | 2015 | 1162 | 0.080 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 342 | 0.080 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2016 | 476 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 1106 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 4893 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 8041 | 0.080 |
Why?
|
| beta Catenin | 1 | 2014 | 1043 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 3 | 2014 | 4772 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 1490 | 0.080 |
Why?
|
| Male | 19 | 2018 | 363698 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2721 | 0.080 |
Why?
|
| Injections | 1 | 2011 | 840 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1774 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6499 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4850 | 0.070 |
Why?
|
| Biopsy | 2 | 2009 | 6763 | 0.070 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 302 | 0.070 |
Why?
|
| Rabbits | 2 | 2011 | 4734 | 0.070 |
Why?
|
| Mice, SCID | 3 | 2018 | 2630 | 0.070 |
Why?
|
| Disease Management | 1 | 2017 | 2535 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2015 | 23601 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2878 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2016 | 3404 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3596 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2018 | 12768 | 0.060 |
Why?
|
| Adult | 13 | 2018 | 223044 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2015 | 1587 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2014 | 2354 | 0.060 |
Why?
|
| Female | 18 | 2018 | 396112 | 0.060 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2005 | 76 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2006 | 405 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2589 | 0.060 |
Why?
|
| Contrast Media | 1 | 2017 | 5329 | 0.060 |
Why?
|
| Laminectomy | 1 | 2005 | 226 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3454 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2013 | 1328 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 3608 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 11022 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2013 | 2850 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2005 | 297 | 0.050 |
Why?
|
| Animals | 8 | 2018 | 168764 | 0.050 |
Why?
|
| Patient Selection | 1 | 2015 | 4255 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 12976 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 3181 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15398 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 3111 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 17594 | 0.050 |
Why?
|
| Middle Aged | 11 | 2018 | 223009 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 4520 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5337 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 3513 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2015 | 6610 | 0.040 |
Why?
|
| Anesthesia | 1 | 2011 | 1590 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2006 | 1069 | 0.040 |
Why?
|
| Acute Disease | 1 | 2009 | 7232 | 0.040 |
Why?
|
| Aged | 7 | 2018 | 171117 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2015 | 65188 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 59489 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 3529 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 9249 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 41649 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 3819 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2014 | 3618 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 16721 | 0.030 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 2045 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2011 | 4424 | 0.030 |
Why?
|
| Adolescent | 3 | 2018 | 88835 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12807 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 16047 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2009 | 20659 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2016 | 268 | 0.030 |
Why?
|
| Radiography | 1 | 2006 | 6919 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2006 | 1917 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2015 | 153 | 0.030 |
Why?
|
| Cystatins | 1 | 2014 | 55 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 508 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 59889 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 244 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2312 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 951 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2014 | 323 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 18071 | 0.030 |
Why?
|
| Serpins | 1 | 2014 | 245 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1446 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1701 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2013 | 1081 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 904 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2016 | 1216 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 746 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 39193 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2013 | 42500 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 1837 | 0.020 |
Why?
|
| Multigene Family | 1 | 2013 | 1080 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2014 | 1965 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 2034 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 1352 | 0.020 |
Why?
|
| Survival Rate | 2 | 2015 | 12795 | 0.020 |
Why?
|
| Exons | 1 | 2014 | 2391 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1884 | 0.020 |
Why?
|
| Mice | 4 | 2018 | 81819 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 1505 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 6113 | 0.020 |
Why?
|
| Microglia | 1 | 2017 | 1372 | 0.020 |
Why?
|
| Virus Replication | 1 | 2016 | 2447 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2017 | 2573 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2505 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4562 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5020 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4108 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 2207 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 3750 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 1370 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 6069 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 18293 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2535 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 27171 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2018 | 2521 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2018 | 81514 | 0.010 |
Why?
|
| Child | 2 | 2013 | 80564 | 0.010 |
Why?
|
| Medical Illustration | 1 | 2005 | 134 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 5786 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 6832 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 7838 | 0.010 |
Why?
|
| Embolism, Fat | 1 | 2003 | 46 | 0.010 |
Why?
|
| Genome, Human | 1 | 2016 | 4448 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13266 | 0.010 |
Why?
|
| Internal Fixators | 1 | 2003 | 183 | 0.010 |
Why?
|
| Rectal Diseases | 1 | 2003 | 141 | 0.010 |
Why?
|
| Cell Movement | 1 | 2014 | 5194 | 0.010 |
Why?
|
| Macrophages | 1 | 2017 | 5772 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 2567 | 0.010 |
Why?
|
| Alleles | 1 | 2013 | 6897 | 0.010 |
Why?
|
| Intestinal Perforation | 1 | 2003 | 253 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 2014 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 4642 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 15747 | 0.010 |
Why?
|
| Chondrosarcoma | 1 | 2003 | 301 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18380 | 0.010 |
Why?
|
| Chordoma | 1 | 2003 | 343 | 0.010 |
Why?
|
| Bone Plates | 1 | 2003 | 469 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8611 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2016 | 10429 | 0.010 |
Why?
|
| Apoptosis | 1 | 2016 | 9514 | 0.010 |
Why?
|
| Time Factors | 2 | 2015 | 40065 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 14448 | 0.010 |
Why?
|
| Risk Factors | 2 | 2018 | 74840 | 0.010 |
Why?
|
| Bone Transplantation | 1 | 2003 | 920 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2003 | 909 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 4860 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2003 | 1543 | 0.010 |
Why?
|
| Spinal Fusion | 1 | 2003 | 1302 | 0.010 |
Why?
|
| Sepsis | 1 | 2003 | 2606 | 0.010 |
Why?
|